SOURCE: Cavit Sciences, Inc.

January 15, 2008 08:00 ET

Cavit Sciences, Inc. Receives $500,000 Financing

DELRAY BEACH, FL--(Marketwire - January 15, 2008) - Cavit Sciences, Inc. ("Cavit") (OTCBB: CVIT) announced that it has received $500,000 pursuant to two Common Stock Purchase Agreements ("Agreements"), executed on November 29, 2007, to fund continued development and growth of the Company. In addition, approximately $4.5 million will be available to Cavit in the event all of the warrants are exercised associated with the Agreements.

Under the terms of the financing, Cavit received the $500,000 through the sale of its common stock to Vision International Enterprises, S.A. and Isthmus Investments Management S.A. ("Investors"). In addition, Cavit will issue the Investors common stock purchase warrants to purchase additional shares at exercise prices ranging from $.40 to $3.00 per share, which can potentially add approximately $4.5 million in capital to Cavit during the next four years. For full details please see Form 8-K.

Colm King, Cavit's CEO, commented, "We knew that a growing business like Cavit Sciences required capital. We are pleased that we have received the support of investors who share our belief in Cavit's potential. Initiating the successful commercialization of our products will make 2008 the defining year for Cavit as an aggressive biotech Company. The Investors' value orientation makes this financing particularly compatible with the creation of long-term value for our shareholders."

"Cavit's management team has proven that they can achieve and maintain exceptional growth with ongoing success," said Sara L. de Nunez, President of Vision International. "We believe that our investment in Cavit will provide the Company with the financial strength to execute strategic opportunities. We look forward to further expanding our relationship with Cavit in the years to come."

There were no broker fees or commissions associated with the financing. The securities issued in this financing have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws, and accordingly may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state and securities laws. The company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in this financing and the shares of common stock issuable upon exercise of the warrants issued in this financing.

Cavit Sciences, Inc. ("Cavit") is a biotechnology company engaged in developing treatments and prevention for cancer, viral infections, opportunistic infections, related diseases and the immune system. Product information and updates will soon be available on Cavit's website. Additional information regarding our drug development, supplement line and Company information is available on the Company's website at:

Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Cavit. These factors include, but are not limited to: (i) the ability of Cavit to successfully raise financing, (ii) the ability of Cavit to finalize its manufacturing and distribution facilities, and (iii) the ability of Cavit to successfully commercialize its products in certain markets. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Cavit's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" for Cavit on Form 10K-SB filed on April 12, 2007 and its subsequently filed Forms 10-QSB.

Contact Information